ASMB: Assembly Biosciences Inc Company Value to Net Income

Symbol and logo of brand Assembly Bio (ASMB)

Assembly Biosciences focuses on the complete eradication of chronic hepatitis B through genetic suppression of the virus. The absence of commercial sales during the trial phase leads to an increase in unit costs as research expands. A critical dependence on external contractors for synthesis and testing defines the business model. This price trend reflected below on GURU.Markets with the -10796.90 indicator visualizes the asset's market dynamics.

ASMB - Assembly Biosciences, Inc. P/E Multiple over the range 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for Assembly Biosciences Inc (ASMB)

- price and consensus price forecast:
Stock Price assemblybio.com|ASMB - Consensus Target
- market capitalization information:
Market Value Assembly Biosciences, Inc.|ASMB - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Assembly Biosciences|ASMB - Book Capitalization|Market Capitalization to Book Value assemblybio.com|ASMB - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Assembly Biosciences|ASMB - Long-Term Debt to Capital|Current Liabilities to Capital Assembly Corp|ASMB - Company Debts|Debt to Net Assets Ratio Assembly Biosciences, Inc.|ASMB - Company Long-Term Debts|Company Short-Term Debts Assembly Biosciences|Interim Coverage Ratio assemblybio.com
- earnings and market ratios statistics:
ASMB - Company Net Income|Company Profit Forecast Assembly Biosciences|ASMB - P/E Multiple|Projected Price to Earnings Ratio Assembly Bio|ASMB - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Assembly Biosciences, Inc.|ASMB - Operating profit EBITDA|Earnings per share for the last twelve months Assembly Biosciences|ASMB - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months assemblybio.com|ASMB - Net earnings per share growth this year|Expected net earnings per share growth next year Assembly Biosciences
Comprehensive company analysis:assemblybio.com - ASMB
Brand item of Assembly Biosciences, Inc.

The valuation of an asset's market value relative to its earnings serves as a key benchmark for determining investment attractiveness. This ratio compares total capitalization with net income, measuring the degree of business overvaluation and its resilience to market shocks. By analyzing the current P/E ratio, an investor identifies the asset's margin of safety or the risk of capital stagnation. For Assembly Biosciences (ASMB), this indicator reflects market expectations for the development of innovative hepatitis B therapies.

Key competitors

P/E Multiple arrowheadpharma.com|Price to Earnings Ratio MIRM (Mirum)|DVAX (Dynavax Technologies) - Company Value to Net Income|Price to Earnings Ratio Arbutus ABUS|Inventiva Corp - Price to Earnings Ratio|Gyre Therapeutics, Inc. - P/E Multiple|Business Payback Period Galectin Therapeutics GALT|GNFT (genfit.com) - Price to Earnings Ratio|DRRX (DURECT) - Price to Earnings Ratio|ALGS (Aligos Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings BioVie Pharma BIVI|Price to Earnings Ratio Galmed Pharmaceuticals (GLMD)|NDRA (endrainc.com) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals, Inc.)